Press Release: Sanofi’s half-year financial report for 2026

 Sanofi’s half-year financial report for 2026

Paris, July 30, 2026. Sanofi announces that its half-year financial report for the period ending June 30, 2026, is now available online and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the US Securities and Exchange Commission (SEC) under form 6-K.

This document may be found on www.sanofi.com and downloaded from the “Investors” page, under the heading “Financial Reports and Other Publications”.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected]
Léo Le Bourhis | + 33 6 75 06 43 81 | [email protected]
Laura Romby| + 33 6 74 16 74 29 | [email protected]

Investor Relations
Thomas Kudsk Larsen |+ 44 7545 513 693 |[email protected]  
Alizé Kaisserian | + 33 6 47 04 12 11 | [email protected] 
Keita Browne | + 1 781 249 1766 | [email protected] 
Nathalie Pham | + 33 7 85 93 30 17 | [email protected] 
Nina Goworek | + 1 908 569 7086 | [email protected]  
Thibaud Châtelet | + 33 6 80 80 89 90 | [email protected]
Yun Li | +33 6 84 00 90 72 | [email protected]
 

Attachment

• Press Release

You May Also Be Interested In

• Biodexa reaches 50% enrollment in Phase 3 FAP trial
• Credit Suisse High Yield Credit Fund approves 1-for-10 reverse share split
• Nebius Group plans $4.5B convertible notes offering in two series